Atopic Dermatitis Market Overview 2025 and Growth US$ 31.68 Bn by 2033 | Japan Insights

Atopic Dermatitis Market reached US$ 10.72 Billion in 2024 and is expected to reach US$ 31.68 Billion by 2033, growing at a CAGR of 13.7% during the forecast period 2025-2033.

Latest Japan‐Related News

Japan's top eczema app "Atopiyo" expands to the US - the app, developed in Japan, is now internationally available

Dupixent (dupilumab) receives approval in Japan for treating atopic dermatitis and other conditions

Maruho to co-develop topical biologic B244 in Japan through a licensing deal with AOBiome

Tapinarof cream (Vtama) approved in Japan for atopic dermatitis in patients 12+

Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/atopic-dermatitis-market?kb

Recent Industry Trends (2025)
Gilead and LEO Pharma Collaboration (Jan 2025): A strategic partnership was formed to advance the STAT6-targeted oral small molecule program aimed at treating inflammatory skin disorders, including atopic dermatitis.

Eli Lilly Acquires Dice Therapeutics (Mar 2025): This acquisition strengthens Lilly's dermatology pipeline by incorporating oral IL-17 inhibitors, expanding therapeutic options for atopic dermatitis (AD).

AI-Powered Dermatology Tools: Artificial intelligence-based skin scanners have been integrated into dermatology applications, enabling real-time skin health monitoring. These tools are increasingly being used in both U.S. and Japanese clinics.

Decentralized Clinical Trials: The adoption of virtual and remote clinical trials continues to grow in 2025. This approach has improved patient recruitment and retention in AD trials by offering virtual consultations and remote monitoring.

Atopic Dermatitis Market Overview

The Atopic Dermatitis encompasses the global industry focused on the diagnosis, treatment, and management of atopic dermatitis (also known as eczema)-a chronic inflammatory skin condition characterized by dry, itchy, red, and inflamed skin. This market includes topical treatments, systemic drugs (like biologics and JAK inhibitors), and emerging digital health solutions

Research Methodology:

The global Atopic Dermatitis Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.

Segment Covered in the Atopic Dermatitis Market:

By Treatment Type: Corticosteroids, Hydrocortisone, Mometasone, Betamethasone, Prednisone, Others , Immunosuppressants , Calcineurin Inhibitors , Cyclosporine, Tacrolimus, Pimecrolimus, Others , JAK Inhibitors , Abrocitinib, Upadacitinib, Others , PDE-4 Inhibitors , Others , Biologics , Dupilumab , Tralokinumab, Others, Antihistamines, Others , , By Patient Type, Children, Adults

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/atopic-dermatitis-market?kb

List of the Key Players in the Atopic Dermatitis Market:

Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Galderma Inc., LEO Pharma Inc., Incyte Corporation, Arcutis Biotherapeutics, Inc., Otsuka Pharmaceutical Co., Ltd, and others.

Atopic Dermatitis Market Emerging Players

The emerging players in the atopic dermatitis market include Almirall, S.A, Aclaris Therapeutics Inc, Kiniksa Pharmaceuticals, Cara Therapeutics, VYNE Therapeutic and among others.

Key Developments in the Atopic Dermatitis Market

April 2025 - Galderma's DTC Campaign: Galderma launched "Scratch Resistance," its first multichannel direct-to-consumer campaign for NEMLUVIO (nemolizumab-ilto). The initiative emphasizes the broader emotional and lifestyle challenges of living with atopic dermatitis, beyond the physical itch.

March 2025 - Amgen & Kyowa Kirin: New insights emerged from the ROCKET Phase 3 trial of rocatinlimab, a therapy that targets the OX40 receptor to rebalance T-cell activity in moderate-to-severe AD patients.

January 2025 - FDA Approves Nemluvio: The U.S. FDA approved Nemluvio (nemolizumab-ilto), a novel IL-31 inhibitor by Galderma, for adolescents and adults with moderate-to-severe atopic dermatitis who are unresponsive to topical therapies.

September 2024 - EBGLYSS Approval: Eli Lilly received FDA approval for EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor designed to treat patients aged 12 and older with moderate-to-severe AD not controlled by topical prescriptions.

April 2024 - Dermavant's VTAMA sNDA: Dermavant announced FDA acceptance of its supplemental NDA for VTAMA (tapinarof) cream, 1%, targeting AD in patients aged 2 and older. A final decision is expected by Q4 2024.

July 2024 - ZORYVE Cream Approval: Arcutis Biotherapeutics secured FDA approval for its sNDA for ZORYVE (roflumilast) cream, 0.15%, offering a non-steroidal treatment for mild-to-moderate AD in patients aged 6 and above. The cream delivers fast relief and supports long-term disease management.

Regional Analysis for Atopic Dermatitis Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Go-to-market Strategy.

➡ Neutral perspective on the market performance.

➡ Customized regional/country reports as per request and country level analysis.

➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➠ What are the global sales, production, consumption, imports, and exports in the Atopic Dermatitis market?

➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?

➠ What key opportunities and challenges do vendors face in the Atopic Dermatitis industry?

➠ Which product types, applications, or end-users are driving market growth, and what is their market share?

➠ What are the major growth drivers and restraints of the Atopic Dermatitis market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.